Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson’s Program – Gain Therapeutics (NASDAQ:GANX)
[ad_1] Gain Therapeutics Inc GANX announced the presentation of new preclinical data evaluating one of its lead Structurally Targeted Allosteric Regulator (STAR) compounds, GT-02287, for Parkinson’s Disease. The study was conducted…
SIGA Announces $16M Procurement Orders For Its Monkeypox Treatment – SIGA Technologies (NASDAQ:SIGA)
[ad_1] SIGA Technologies Inc SIGA received approximately $16 million in international procurement orders for oral TPOXX (tecovirimat) in August and early September. The orders include an approximate $10 million order by…
LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen – Seagen (NASDAQ:SGEN)
[ad_1] Seagen Inc SGEN has announced an exclusive license agreement to develop, manufacture and commercialize LAVA Therapeutics N.V.’s LVTX LAVA-1223. LAVA-1223 is a preclinical asset that utilizes LAVA’s proprietary Gammabody technology to target…
Despite Regulatory Setback, Spectrum Still “Unique Investment Opportunity,” Says Analyst – Spectrum Pharmaceuticals (NASDAQ:SPPI)
[ad_1] Yesterday, the FDA’s Oncologic Drugs Advisory Committee (ODAC) panel voted against Spectrum Pharmaceuticals Inc’s SPPI poziotinib’s (pozi) risk/benefit ratio and concluded that pozi’s benefits do not outweigh the risks for the…
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings – Citius Pharmaceuticals (NASDAQ:CTXR)
[ad_1] Citius Pharmaceuticals Inc CTXR collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company, Inc. MRK Keytruda (pembrolizumab) for recurrent or metastatic solid tumors. …